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University of Manchester, Manchester, UK; and 3School of Psychological Sciences, University of Manchester, Manchester, UKIntroduction: Kidney disease is associated with signiﬁcant cognitive dysfunction. Subjective reports
of cognitive ability have not been studied extensively in chronic kidney disease. We investigated the
association between objective and subjective cognitive functions in predialysis patients and their
association with self-care dialysis modality choice.
Methods: Cross-sectional data from the Barriers to Successful Implementation of Care in Home Haemo-
dialysis study were used for the study of cognition in 220 predialysis patients. The data were used to
ascertain the demographics, clinical, laboratory, and neuropsychometric variables. The latter includes
Trail Making Tests (TMT) parts A and B, Modiﬁed Mini Mental State Examination, and metacognition
questionnaire for subjective assessment of one’s cognitive ability. The outcome variable was fully assisted
and self-care dialysis modality choice.
Results: Within the study cohort, 90 patients chose fully assisted hemodialysis and 114 patients chose
self-care dialysis. The median Modiﬁed Mini Mental State Examination, TMT part A, and TMT part B scores
weregreater for theassistedversus theself-caregroup.Metamemorywasnot signiﬁcantlydifferent between
groups, but the metaconcentration score was signiﬁcantly worse in the group choosing assisted dialysis.
Higher (i.e., better)metaconcentrationscoresweresigniﬁcantly associatedwith theself-caremodality choice
in the univariate and hierarchical regression analyses. Adjusted and unadjusted analyses showed a signif-
icant association between perceived concentration and TMT part B scores (P< 0.01). With every 1.6-minute
increase in TMT part B score, there was a 1-unit reduction in metaconcentration score, and the latter was
associated with 20% lower odds of choosing self-care dialysis over a fully assisted dialysis modality.
Discussion: Patients’ self-perception of cognitive ability is a signiﬁcant predictor of self-care dialysis
modality choice. Subjective report of “metaconcentration” is also strongly associated with poorer
outcome on the TMT part B.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C hronic kidney disease (CKD) is a worldwide publichealth issue.1,2 Cognitive deﬁcits in CKD patients
are increasingly being recognized as a major problem,
with a 3-fold increase in this group compared to that in
the general population.3 The management of cognitive
deﬁcits very early in the course of CKD is desirable,
as more advanced stages of kidney disease are associ-
ated with greater impairment of cognitive function.4
In 1 study, participants with mild, moderate, and se-
vere renal impairment were compared, and the authorsspondence: Anuradha Jayanti, Department of Nephrology,
hester Royal Inﬁrmary, Oxford Road, Manchester, United
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published online 10 August 2016concluded that for every 10-ml/min decrease in esti-
mated glomerular ﬁltration rate, the risk of cognitive
dysfunction increased by 15% to 25%.5 This issue is
more of a problem in older individuals and in those
established on dialysis, with a prevalence of cognitive
impairment in hemodialysis patients estimated to be
about 30% to 70%.6 The presence of cognitive impair-
ment in this cohort is also associated with higher mor-
tality.7,8 The pathogenesis of the accelerated cognitive
decline in CKD is attributable to vascular injury from
traditional risk factors, and from direct neuronal
toxicity of uremic retention solutes.9 It is believed
that microvascular disease of the brain is responsible
for the pattern of cognitive deﬁcits seen in kidney dis-
ease and that it is related to the patients’ vascular risk
proﬁles. This is typically manifest as impaired execu-
tive brain function.Kidney International Reports (2016) 1, 240–249
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tant, as the notion of self-care dialysis relies on cognitive
intactness. Patient participation, patient choice, and
patient-led decision making are associated with better
outcomes and are therefore considered best clinical
practice.10–12 There is greater impetus for self-
management of long-term conditions,13,14 but the
cognitive context in which such decisions are made by
patients is not well understood and merits further
research. This applies to both objective cognitive deﬁ-
cits and patients’ assessment of their own cognitive
ability (subjective cognitive ability). The latter
is grossly underrepresented in kidney disease literature.
Few studies have been published to date, in regard to
patients with kidney disease, that speciﬁcally seek to
examine the association between subjective and objec-
tive cognition assessments.15,16 The Kidney Disease
Quality of Life (KDQOL)Cognitive Function subscale
with 3 questions was shown to be a limited instrument
for accurately assessing subjective cognitive function16
and bore no relationship to the executive function test,
which is commonly abnormal in chronic kidney dis-
ease.17–19 More recently, a study found modest correla-
tion between subjective and objective assessments;
however, the former was a predictor of the patient’s self-
reported measure of activities of daily living, although
both subjective reports may well be inﬂuenced by
negative affectivity.15,20 In other population groups,
subjective assessment of impaired cognition has been
associated with poorer health-related quality-of-life,
reduced daily functioning,21 and increased risk of hos-
pital attendance,22,23 and is also predictive of future
cognitive decline.24–26 In addition, the identiﬁcation of
cognitive impairment is important in order to assist pa-
tients in making well-informed treatment decisions, in
ensuring treatment compliance, and in helping to pre-
vent functional decline.27 Treatment decision making is
multifactorial and includes, among other factors, the
patient’s and health care professional’s perception
(whether accurate or not) of the patient’s cognitive abil-
ities. The choice of self-care dialysis decisions is expected
of patients after information on dialysis modalities is
provided to them. Hence, the possibility of the inﬂuence
of the patients’ assessment of how their memory works,
and how they judge their own abilities and effectiveness,
may predict their choice of dialysis modality.
The aims of the present study are as follows: (1)
to assess metacognition in patients with CKD-5 (pre-
dialysis phase of end-stage renal disease) as a measure
of subjective cognitive impairment and to explore the
association between subjective and objective cognition
tests; and (2) to examine associations of dialysis mo-
dality choice (fully assisted vs. self-care) with measures
of objective (global cognition and executive brainKidney International Reports (2016) 1, 240–249function) and subjective cognition assessments (mem-
ory and concentration).
MATERIALS AND METHODS
Participants and Recruitment
Data for the present study are derived from that ascer-
tained for the Barriers to Successful Implementation of
Care in Home Haemodialysis (BASIC-HHD) study.28 The
data were prospectively collected for a comprehensive
and systematic study of barriers to and enablers of the
uptake of self-care dialysis therapy. The study involves
5 centers in the United Kingdom, with variable preva-
lence rates of home hemodialysis (HD). An integrated
mixed methodology (convergent, parallel design) has
been adopted for the BASIC-HHD study in a combined
cross-sectional and prospective study design. The
methodological details and scope of data collected in the
BASIC-HHD appear in a published protocol.28 Data
presented here are derived from the CKD-5, a predialysis
cohort of the BASIC-HHD study. A total of 222 patients
were enrolled in this group. Predialysis patients were
approached if they fulﬁlled eligibility criteria and were
willing to undertake neuropsychometric assessments
and to complete study speciﬁc questionnaires.
Study Registration
This study was reviewed and approved by the Greater
Manchester West Health Research Authority National
Research Ethics Service (NRES) (Reference number:
12/NW/0170). The study is on the NIHR portfolio
(ID 12346). Written informed consent from participants
was obtained for the study. Psychological measures
used in this study were part of a compilation of ques-
tionnaires. Blood sampling and neuropsychometric
assessments were carried out at patients’ routine hos-
pital clinic visits. Visually impaired participants were
excluded from this analysis (n ¼ 2).
Independent Variables
Independent variables included the following: objective
tests of cognition, Trail Making Tests (TMT) parts A and
B,29 Modiﬁed Mini Mental State Examination (3MS),30
subjective assessment of cognition scales (metacogni-
tion questionnaire,31 demographics (age, sex, ethnicity,
education, employment, and marital status); clinical
variables (Charlson Comorbidity Index [CCI],32 cause of
end-stage renal disease [ESRD], diabetes, heart failure,
intracranial vascular events, ischemic heart disease,
systolic and diastolic blood pressures); laboratory vari-
ables (urea, creatinine, phosphate, parathyroid hormone,
bicarbonate, albumin, hemoglobin, and medications
including angiotensin-converting enzyme inhibitors,
central nervous systeminﬂuencing drugs, antidepres-
sants, antiplatelet agents, cholesterol-lowering drugs,241
Table 1. Completeness of data provided by study participants
Number of eligible participants 220
TMT part A 208 (94.5%)
TMT part B 169 (76.8%)
3MS 206 (93.6%)
Metamemory subscale 215 (97.7%)
Metaconcentration subscale 213 (96.8%)
Decision on modality choice (outcome variable) 204 (92.7%)
CLINICAL RESEARCH A Jayanti et al.: Cognitive Impairment in ESRD and Dialysis Modality Choiceerythropoietin, folic acid, and number of antihyperten-
sive drugs and total pill burden); and psychological
screening tools (Beck Depression Inventory [BDI],33 and
State and Trait Anxiety Inventory (STAI).34
Cognitive Assessments
Objective Tests
Tests of cognitive function were assessed by study
coordinators across all participating centers after
completion of training in the application and procedure
for using these tests. Only participants conversant in
English language were included in this aspect of the
study. The 3MS is a test of global cognitive function
that includes assessment of orientation, attention,
calculation, language, and short-term memory. The
Trail Making Tests are a measure of cognitive abilities
such as speed and ﬂuid intelligence; they have been
hypothesized to reﬂect a wide variety of cognitive
processes including attention, visual search and scan-
ning, sequencing and set shifting, psychomotor speed,
abstraction, ﬂexibility, and ability to execute and
modify a plan of action. A 3MS score of <80 is deemed
deﬁcient. The timed Trail Making Tests parts A and B
are deemed insufﬁcient if the duration exceeds 1 SD
from the mean of the present study cohort (>87
seconds in part A and >197 seconds in part B). All
3 variables were treated as continuous variables
for the purpose of the univariate and multivariable
analysis.
Subjective Tests
To enable understanding of the patients’ beliefs about
their own memory and concentration, the brief meta-
cognition questionnaire was used. This questionnaire
has 2 subscales: the metamemory subscale (5 questions)
and the metaconcentration subscale (4 questions).
Metacognition is highly relevant for sustained inde-
pendence in older age. This tool has not been validated
in the kidney disease population, but the parameters
used to assess the outcome, namely independence, was
deemed common to both population groups. The
responses were given on a Likert scale (1 ¼ strongly
disagree, 2 ¼ disagree, 3 ¼ neither agree nor disagree,
4 ¼ agree and 5 ¼ strongly agree) and then summed for
each subscale. The range of scores for the metamemory
subscale is 5 to 25 and that of the metaconcentration
subscale is 4 to 20. A summary of completeness of data
provided by the study participants is provided in
Table 1.
The TMT part B test data had missing data points
that appeared to be missing at both random and not at
random. Where patients failed to complete part of the
test, the data are considered “missing not at random.”
Missing at random data included those items for which
participants did not complete any data or for which the242administration was deemed incorrect. In 8 cases, the
data were imputed to 300 seconds where the adminis-
trator explicitly mentioned that the patient “gave up”
completing the TMT part B test after persisting for
some time (missing not at random data). However, of
these 8 imputed cases, only 6 were considered for
analysis, for which information on modality choice as
the outcome was also available.
Statistical Analyses
Analyses were performed using SPSS 22 and STATA
13. A 2-sided 5% signiﬁcance level was used
throughout the analysis. Baseline characteristics were
assessed among the 3 modality choices in the pre-
dialysis cohort using c2 tests, Fisher exact tests, ana-
lyses of variance, and KruskalWallis tests, as
appropriate.
Single variable analyses using c2 tests, Fisher exact
tests, independent t tests, and MannWhitney U tests,
as appropriate, with modality choice as the outcome,
grouped as self-care (peritoneal dialysis [PD] and home
dialysis) and hospital, revealed which cognitive, med-
ical, and demographic variables were signiﬁcant. A
hierarchical logistic regression analysis was then car-
ried out for each of the cognitive variables (5 models)
with modality choice as the outcome. The differences
within the self-care group were investigated to assess
the suitability of grouping PD and home HD. The re-
lationships between the subjective and objective
cognition variables were investigated using correla-
tions and linear regression.
Sensitivity analyses were carried out involving
multiple imputation with chained equations to account
for missing data in all of the cognition variables based
on variables including CCI, age, sex, ethnicity, educa-
tion, employment, BDI, scores on other tests of objec-
tive cognition, and the outcome variable, namely,
modality choice (Appendix S1).
RESULTS
Patient Characteristics
There were 220 participants in all. A total of 90 patients
chose hospital hemodialysis and 114 patients chose self-
care dialysis (PD and home hemodialysis [HHD]). Of
these, 52% (114) of patients expressed their preferenceKidney International Reports (2016) 1, 240–249
Table 2. Characteristics of study participants
Facility-based HD (n [ 90) PD (n [ 78) Home HD (n [ 36) P value
TMT B, median (IQR) n ¼ 64
102.0 (78.5–132.3)
n ¼ 63
90.0 (63.0–118.0)
n ¼ 30
94.0 (64.5–122.5)
0.11a
TMT A, median (IQR) n ¼ 83
49.0 (32.0–62.0)
n ¼ 74
41.5 (30.0–60.0)
42.8 (31.2–55.9) 0.086a
3MS, median (IQR) n ¼ 85
93.0 (88.5–97.0)
n ¼ 74
95.0 (91.0–98.0)
n ¼ 34
92.5 (88.0–96.5)
0.066a
MCQ1 (metamemory), mean (SD) n ¼ 89
17.7 (3.8)
n ¼ 76
18.2 (3.3)
n ¼ 35
17.4 (4.5)
0.53b
MCQ2 (metaconcentration), mean (SD) n ¼ 88
13.9 (2.4)
n ¼ 74
15.1 (2.8)
14.6 (2.9) 0.016b
Age, mean (SD) 62.6 (12.3) 58.3 (12.9) 53.6 (13.0) 0.001b
Sex, female 36 (40.0%) 28 (35.9%) 15 (41.7%) 0.80c
Education, post high school 19/87 (21.8%) 20/76 (26.3%) 12/35 (34.3%) 0.36c
Employment
Retired 51 (56.7%) 36 (46.2%) 12 (33.3%)
Unemployed 19 (21.1%) 13 (16.7%) 7 (19.4%) 0.053c
Salaried/self-employed 20 (22.2%) 29 (37.2%) 17 (47.2%)
Ethnicity, nonwhite 12 (13.3%) 3 (3.8%) 5 (13.9%) 0.079c
Marital status
Married or partner 56 (62.2%) 53 (67.9%) 23 (63.9%)
Single 20 (22.2%) 13 (16.7%) 7 (19.4%) 0.71d
Divorced or separated 6 (6.7%) 3 (3.8%) 4 (11.1%)
Widowed 8 (8.9%) 9 (11.5%) 2 (5.6%)
Cause of ESRD
Systemic 50 (55.6%) 29 (37.2%) 13 (36.1%)
Renal 17 (18.9%) 24 (30.8%) 13 (36.1%) 0.081c
Other/unknown 23 (25.6%) 25 (32.1%) 10 (27.8%)
CCI, median (IQR) 5.0 (4.0–7.0) 4.0 (3.0–6.0) 4.0 (3.0–5.0) 0.009a
Diabetes 32 (35.6%) 22 (28.2%) 10 (27.8%) 0.52c
Heart failure 4 (4.4%) 4 (5.1%) 1 (2.8%) >0.99d
Ischemic heart disease 18 (20.0%) 18 (23.1%) 6 (16.7%) 0.72c
IVE 9 (10.0%) 5 (6.4%) 2 (5.6%) 0.59c
Urea, median (IQR) n ¼ 89
22.6 (18.6–28.2)
n ¼ 77
23.1 (18.6–29.4)
n ¼ 34
23.1 (19.7–26.0)
0.86a
Creatinine, median (IQR) n ¼ 89
377 (338–459)
n ¼ 77
428 (343–524)
n ¼ 34
429 (383–500)
0.046a
Hb < 9 3/89 (3.4%) 2/77 (2.6%) 2/35 (5.7%) 0.77d
Alb < 30 4/89 (4.5%) 2/77 (2.6%) 0/35 (0%) 0.65d
Bic n ¼ 84 n ¼ 75 n ¼ 35
<22 37 (44.0%) 32 (42.7%) 17 (48.6%)
22–28 43 (51.2%) 39 (52.0%) 17 (48.6%) 0.99d
>28 4 (4.8%) 4 (5.3%) 1 (2.9%)
PTH, median (IQR) n ¼ 86
23.6 (14.0–35.2)
n ¼ 77
22.2 (12.3–35.1)
n ¼ 35
32.3 (17.5–48.3)
0.051a
Phosphate n ¼ 88 n ¼ 76 n ¼ 35
<1.1 11 (12.5%) 11 (14.5%) 2 (5.7%)
1.1–1.7 61 (69.3%) 43 (56.5%) 28 (80.0%) 0.14c
>1.7 16 (18.2%) 22 (28.9%) 5 (14.3%)
SBP, #115 4/89 (4.5%) 9/76 (11.8%) 1 (2.8%) 0.10c
SBP, mean (SD) n ¼ 89
143.7 (19.2)
n ¼ 76
137.5 (21.4)
140.1 (17.5) 0.14b
DBP, >85 16/89 (18.0%) 15/76 (19.7%) 6 (16.7%) 0.92c
DBP, mean (SD) n ¼ 89
76.3 (11.1)
n ¼ 76
77.1 (11.4)
73.4 (11.9) 0.26b
ACEI or ARB 41 (45.6%) 47 (60.3%) 21/34 (61.8%) 0.098c
Folic acid 10 (11.1%) 11 (14.1%) 5/34 (14.7%) 0.80c
No. of antihypertensive drugs, median (IQR) 3.0 (2.0–4.0) 2.5 (2.0–4.0) n ¼ 34
3.0 (2.0–4.0)
0.28a
EPO 31 (34.4%) 30 (38.5%) 8/35 (22.9%) 0.27c
CNS 7 (7.8%) 7 (9.0%) 4/34 (11.8%) 0.79c
Antidepressants 18 (20.0%) 10 (12.8%) 3/34 (8.8%) 0.22c
(Continued on next page)
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Table 3. Participants with cognitive deﬁcits, by dialysis type
Overall Hospital PD Home HD
3MS (<80) 6/193 (3.1%) 3/85 (3.5%) 1/74 (1.4%) 2/34 (5.9%)
TMT part A (>87) 15/193 (7.8%) 7/83 (8.4%) 6/74 (8.1%) 2/36 (5.6%)
TMT part B (>197) 12/157 (7.6%) 6/64 (9.4%) 3/63 (4.8%) 3/30 (10.0%)
Home HD; home hemodialysis; PD, peritoneal dialysis; TMT, Trail Making Test.
Table 2. Characteristics of study participants (Continued)
Facility-based HD (n [ 90) PD (n [ 78) Home HD (n [ 36) P value
Antiplatelet agents 39 (43.3%) 24 (30.8%) 13/34 (38.2%) 0.24c
Statins/EZE 53 (58.9%) 41 (52.6%) 24/34 (70.6%) 0.20c
Pill burden, mean (SD) 7.5 (2.6) 6.9 (2.5) n ¼ 34
8.2 (3.4)
0.069b
BDI, median (IQR) n ¼ 82
12.0 (5.8–22.3)
n ¼ 70
7.0 (4.0–12.3)
n ¼ 28
9.0 (6.0–14.5)
0.009a
STAI State, median (IQR) n ¼ 80
39.5 (29.3–47.8)
n ¼ 66
32.0 (26.0–40.0)
n ¼ 28
33.0 (25.3–46.0)
0.026a
STAI Trait, median (IQR) n ¼ 79
41.0 (30.0–47.0)
n ¼ 63
34.0 (29.0–46.0)
n ¼ 28
35.0 (27.0–42.8)
0.093a
BDI, Beck Depression Inventory; CCI, Charlson Comorbidity Index; CNS, central nervous system; DBP, diastolic blood pressure; EPO, erythropoeitin; ESRD, end-stage renal disease;
EZE, ezetemibe; HD, hemodialysis; IVE, intracranial vascular event; IQR, interquartile range; MCQ, Metacognition Questionnaire; PD, peritoneal dialysis; PTH, parathyroid hormone;
SBP, systolic blood pressure; STAI, State and Trait Anxiety Inventory; TMT, Trail Making Test; 3MS, Modiﬁed Mini Mental State Examination.
aKruskalWallis test.
bOne-way analysis of variance.
cPearson c2 test.
dFisher exact test.
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patients preferred PD. The characteristics of these
participants are presented in the Table 2. Among the 3
groups overall, signiﬁcant differences were observed in
regard to age, CCI, BDI score, and STAI-S, which were
higher in patients choosing fully assisted dialysis.
Metaconcentration scores were lowest in participants
choosing hospital HD. Parathyroid hormone was
signiﬁcantly higher in the cohort choosing HHD.
Within the self-care group, no signiﬁcant differences
were observed in any dependent variable category,
including tests of cognition, between participants who
chose PD versus HHD.
Cognition Burden in ESRD
In the study cohort, based on the cut-off for identiﬁ-
cation of objective cognitive deﬁcit (3MS < 80, TMT
parts A and B > 1.5 SD from the mean for the study
groups), the numbers and proportions of participants
with cognitive deﬁcits in the 3 groups are as shown in
Table 3.
Univariate Analysis
In the single-variable analysis of the association of key
variables of interest with modality choice (Table 4),
variables signiﬁcantly (P < 0.05) associated with self-
care dialysis modality (PDþHHD) choice, include
lower TMT part B scores, lower TMT part A scores,
higher metaconcentration scores, lower age, being in
employment, “renal-limited” cause of end-stage renal
disease, lower CCI, use of drugs such as angiotensin-
converting enzyme inhibitors, higher serum creati-
nine, lower BDI, and lower STAI-S/T scores.
Hierarchical Regression Analysis of Predictors
of Self-Care Modality Choice
In the hierarchical regression analysis (Table 5), signiﬁ-
cant predictors of self-care dialysis modality choice
across all models of cognition tests include white244ethnicity, lower BDI scores, and lower CCI, after adjust-
ment for other variables in the model. The test of sub-
jective cognitive ability, themetaconcentration subscale,
but not the metamemory subscale, was highly signiﬁ-
cantly associated with self-care modality choice (P <
0.01). TMT parts A and B and 3MS were not statistically
signiﬁcant predictors ofmodality choice after adjustment
for CCI (age is factored into CCI), BDI, employment,
ethnicity, and sex, although the direction of effect sug-
gests that better scores on tests of cognition are associated
with the choice of self-care dialysis modality.
Association Between Objective and Subjective
Cognitive Assessments
In the adjusted analysis (adjusted for CCI, BDI, and
education) (Table 6) of the association among TMT
parts A and B, 3MS, and the metamemory and meta-
concentration subscales, a signiﬁcant association was
noted between TMT part B and the metaconcentration
scale (P < 0.01). A parameter estimate of 0.10 sug-
gests a small (0.1-unit) change in metaconcentration
score with a 10-second increase in TMT part B.
Therefore, with every 1.6-minute increase in TMT part
B, there is a 1-unit reduction in metaconcentration
score, and this is associated with 20% lower odds of
choosing a self-care modality over HDD.
DISCUSSION
The cognitive ability assessment of predialysis CKD-5
patients is a window into the patient’s ability to
ascertain, retain, and process information and to comeKidney International Reports (2016) 1, 240–249
Table 4. Univariate analysis of study variables with modality choice
as outcome
Facility-based HD
(n [ 90)
Self-care,
Home HD or
PD (n [ 114) P value
TMT B, Median (IQR) n ¼ 64
102.0 (78.5–132.3)
n ¼ 93
90.0 (63.0–119.0)
0.043a
TMT A, Median (IQR) n ¼ 83
49.0 (32.0–62.0)
n ¼ 110
42.0 (30.0–56.3)
0.029a
3MS, Median (IQR) n ¼ 85
93.0 (88.5–97.0)
n ¼ 108
94.5 (91.0–98.0)
0.063a
MCQ1 (metamemory),
Mean (SD)
n ¼ 89
17.7 (3.8)
n ¼ 111
17.9 (3.7)
0.61b
MCQ2 (metaconcentration),
Mean (SD)
n ¼ 88
13.9 (2.4)
n ¼ 110
14.9 (2.8)
0.006b
Age, Mean (SD) 62.6 (12.3) 56.8 (13.1) 0.001b
Gender, Female 36 (40.0%) 43 (37.7%) 0.74c
Education, post-high school 19/87 (21.8%) 32/111 (28.8%) 0.26c
Employment
Retired 51 (56.7%) 48 (42.1%)
Unemployed 19 (21.1%) 20 (17.5%) 0.022c
Salaried/self-employed 20 (22.2%) 46 (40.4%)
Ethnicity, nonwhite 12 (13.3%) 8 (7.0%) 0.13c
Marital status
Married or partner 56 (62.2%) 76 (66.7%)
Single 20 (22.2%) 20 (17.5%) 0.86c
Divorced or separated 6 (6.7%) 7 (6.1%)
Widowed 8 (8.9%) 11 (9.6%)
Cause of ESRD
Systemic 50 (55.6%) 42 (36.8%)
Renal 17 (18.9%) 37 (32.5%) 0.020c
Other/Unknown 23 (25.6%) 35 (30.7%)
CCI, Median (IQR) 5.0 (4.0–7.0) 4.0 (3.0–6.0) 0.003a
Diabetes 32 (35.6%) 32 (28.1%) 0.25c
Heart failure 4 (4.4%) 5 (4.4%) >0.99d
Ischaemic Heart Disease 18 (20.0%) 24 (21.1%) 0.85c
IVE 9 (10.0%) 7 (6.1%) 0.31c
Urea, Mean (SD) n ¼ 89
23.3 (7.7)
n ¼ 111
24.0 (6.6)
0.51b
Creatinine – Median (IQR) n ¼ 89
377 (338–459)
n ¼ 111
428 (348–513)
0.013a
Hb, <9 3/89 (3.4%) 4/112 (3.6%) >0.99d
Alb, <30 4/89 (4.5%) 2/112 (1.8%) 0.41d
Bic n ¼ 84 n ¼ 110
<22 37 (44.0%) 49 (44.5%)
22–28 43 (51.2%) 56 (50.9%) 0.93e
>28 4 (4.8%) 5 (4.5%)
PTH, Median (IQR) n ¼ 86
23.6 (14.0–35.2)
n ¼ 112
25.2 (13.2–38.2)
0.45a
Phosphate n ¼ 88 n ¼ 111
<1.1 11 (12.5%) 13 (11.7%)
1.1–1.7 61 (69.3%) 71 (64.0%) 0.40e
>1.7 16 (18.2%) 27 (24.3%)
SBP, #115 4/89 (4.5%) 10/112 (8.9%) 0.22c
SBP, Mean (SD) n ¼ 89
143.7 (19.2)
n ¼ 112
138.4 (20.2)
0.059b
DBP, >85 16/89 (18.0%) 21/112 (18.8%) 0.89c
DBP, Mean (SD) n ¼ 89
76.3 (11.1)
n ¼ 112
75.9 (11.6)
0.81b
ACEI or ARB 41 (45.6%) 68/112 (60.7%) 0.032c
Folic acid 10 (11.1%) 16/112 (14.3%) 0.50c
Number of antihypertensive
drugs, Median (IQR)
3.0 (2.0–4.0) n ¼ 112
3.0 (2.0–4.0)
>0.99a
(Continued)
Table 4. Characteristics of study participants (Continued)
Facility-based HD
(n [ 90)
Self-care,
Home HD or
PD (n [ 114) P value
EPO 31 (34.4%) 38/113 (33.6%) 0.90c
CNS 7 (7.8%) 11/112 (9.8%) 0.61c
Antidepressants 18 (20.0%) 13/112 (11.6%) 0.10c
Antiplatelets 39 (43.3%) 37/112 (33.0%) 0.13c
Statins/EZE 53 (58.9%) 65/112 (58.0%) 0.90c
Pill burden, mean (SD) 7.5 (2.6) n ¼ 112
7.3 (2.9)
0.65b
BDI, median (IQR) n ¼ 82
12.0 (5.8–22.3)
n ¼ 98
7.5 (4.0–13.0)
0.005a
STAI State, median (IQR) n ¼ 80
39.5 (29.3–47.8)
n ¼ 94
32.0 (26.0–42.3)
0.010a
STAI Trait, median (IQR) n ¼ 79
41.0 (30.0–47.0)
n ¼ 91
35.0 (29.0–45.0)
0.049a
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI,
Charlson Comorbidity Index; CNS, central nervous system; DBP, diastolic blood pres-
sure; EPO, erythropoeitin; ESRD, end-stage renal disease; EZE, ezetemibe; HD, hemo-
dialysis; IQR, interquartile range; MCQI, Metacognition Questionnaire 1; PD, peritoneal
dialysis; PTH, parathyroid hormone; SBP, systolic blood pressure; STAI, State and Trait
Anxiety Inventory; 3MS, Modiﬁed Mini Mental State Examination.
aMannWhitney U test.
bIndependent-samples t test.
cPearson c2 test.
dFisher exact test.
ec2 linear trend test.
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Kidney International Reports (2016) 1, 240–249to a rational, wellthought-through decision in a hy-
pothetical context. In the choice of self-care dialysis,
multiple cognitive processes enable the individual to
shift perceptions from the chronic predialysis state to
an alternative, imagined perspective on treatment
dialysis, through culmination of learning experiences
from the past, planning, prediction of imagined events,
insight, creativity, and emotional responses. The com-
plex neurobiology of cognition in the face of emotion
and affective disorders that CKD patients experience is
relatively under-researched. However, impairments in
cognitive ﬂexibility and contextual abstraction have
been found in other conditions, such as Parkinson
disease and depression, with regard to goal-directed
behavior and adaptive decision making.35 In a recent
publication from our study group, we demonstrated
that the lowest tertile of decision-making scores on a
decision-making scale was in fact associated with
poorer scores on tests of executive brain function.36
Our study has attempted to explore the association
between measured cognitive deﬁcits and self-care
dialysis modality choice. The inﬂuence of patients’
assessment of how their memory works, and how they
judge their own abilities and effectiveness, may predict
their choice of dialysis modality; therefore, a pragmatic
brief tool to measure subjective cognitive capacity has
been studied here.31 This is the ﬁrst study of its kind in
the dialysis choice context. The data completeness rate
for all aspects of the study combined is excellent.
Our ﬁndings suggest that greater cognitive ability is
associated signiﬁcantly with greater self-care dialysis245
Table 5. Hierarchical regression analysis of cognition variables with
modality choice outcomea
Variable Odds ratio (95% CI) P value
First stage (employment, CCI, and BDI)
Employment Retired 1 ()
Unemployed 1.12 (0.44, 2.85) 0.41
Salaried/self-employed 1.68 (0.77, 3.68)
CCI (per unit increase) 0.85 (0.71, 1.01) 0.066
BDI (per 10-unit increase) 0.67 (0.49, 0.93) 0.018
Second stage (ethnicity and sex)
Employment Retired 1 ()
Unemployed 1.35 (0.51, 3.56) 0.30
Salaried/self-employed 1.88 (0.84, 4.20)
CCI (per unit increase) 0.83 (0.70, 0.99) 0.038
BDI (per 10-unit increase) 0.69 (0.50, 0.96) 0.029
Ethnicity, nonwhite 0.26 (0.08, 0.90) 0.033
Sex, female 0.86 (0.45, 1.64) 0.65
Third stage (TMT B variable added) 137/220 (62.3%)
Employment Retired 1 () 0.10
Unemployed 1.34 (0.42, 4.24)
Salaried/self-employed 2.88 (1.08, 7.70)
CCI (per unit increase) 0.87 (0.71, 1.08) 0.22
BDI (per 10-unit increase) 0.74 (0.50, 1.09) 0.13
Ethnicity, nonwhite 0.13 (0.03, 0.62) 0.010
Sex, female 0.90 (0.42, 1.93) 0.78
TMT B (per 10-s increase) 0.96 (0.90, 1.02) 0.16
Third stage (TMT A variable added) 170/220 (77.3%)
Employment Retired 1 ()
Unemployed 1.69 (0.60, 4.76) 0.29
Salaried/self-employed 1.91 (0.83, 4.37)
CCI (per unit increase) 0.85 (0.70, 1.02) 0.084
BDI (per 10-unit increase) 0.66 (0.47, 0.94) 0.021
Ethnicity, nonwhite 0.28 (0.08, 0.98) 0.046
Sex, female 0.86 (0.44, 1.69) 0.67
TMT A (per 10-s increase) 0.91 (0.79, 1.05) 0.21
Third-stage (3MS variable added) 172/220 (78.2%)
Employment Retired 1 ()
Unemployed 1.44 (0.53, 3.93) 0.53
Salaried/self-employed 1.61 (0.69, 3.73)
CCI (per unit increase) 0.85 (0.71, 1.03) 0.097
BDI (per 10-unit increase) 0.66 (0.47, 0.94) 0.020
Ethnicity, nonwhite 0.28 (0.08, 0.97) 0.044
Sex, female 0.85 (0.44, 1.65) 0.63
3MS (per 10 increase in score) 1.59 (0.86, 2.96) 0.14
Third stage (metamemory variable added) 178/220 (80.9%)
Employment Retired 1 () 0.24
Unemployed 1.47 (0.55, 3.94)
Salaried/self-employed 2.02 (0.90, 4.53)
CCI (per unit increase) 0.83 (0.69, 0.99) 0.038
BDI (per 10-unit increase) 0.67 (0.48, 0.95) 0.023
Ethnicity, nonwhite 0.26 (0.08, 0.91) 0.035
Gender, Female 0.86 (0.45, 1.64) 0.64
Metamemory (per unit increase in score) 1.01 (0.93, 1.10) 0.80
Third stage (metaconcentration variable added) 175/220 (79.5%)
Employment Retired 1 () 0.22
Unemployed 1.49 (0.53, 4.20)
Salaried/self-employed 2.09 (0.91, 4.79)
CCI (per unit increase) 0.79 (0.66, 0.95) 0.013
BDI (per 10-unit increase) 0.75 (0.52, 1.08) 0.12
Ethnicity, nonwhite 0.28 (0.08, 0.99) 0.048
Sex, female 0.82 (0.42, 1.61) 0.56
(Continued)
Table 5. Characteristics of study participants (Continued)
Variable Odds ratio (95% CI) P value
Metaconcentration (per unit increase in
score)
1.20 (1.05, 1.37) 0.008
BDI, Beck Depression Inventory; CI, conﬁdence interval; CCI, Charlson Comorbidity
Index; OR, odds ratio; s, second; TMT, Trail Making Test; 3MS, Modiﬁed Mini-Mental
State.
aOR >1 ¼ Self-care modality choice.
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246modality choice. Patients’ self-reported metaconcen-
tration however, is highly signiﬁcantly associated with
self-care dialysis modality choice. None of the 3 mea-
sures of objective cognition assessments, however, is
statistically signiﬁcant in the regression models. The
objective tests of cognition lack statistical power. The
data that are systematically missing because of patients’
inability to complete the test indicates that there could
potentially have been a statistically signiﬁcant associ-
ation if patients had persevered and completed the
tests. However, it is to be noted that recruitment and
retention of patients in studies of cognition is difﬁ-
cult27,37 and may pose a major limitation with respect
to practical clinical utility.
The metacognition questionnaire captures patients’
beliefs about their memory and concentration compo-
nents of the cognition process, and it is important, as
not every functional area of the brain is affected
equally in patients. In an otherwise healthy group of
elderly patients, 1 study reported that individuals
lacking in self-concept show less problem solving,
perhaps because they do not think it is worth trying.38
If cognitive decline is consciously perceived by
individuals, they may no longer practice their cogni-
tive skills and may rely on external assistance.39 Our
study does show a statistically signiﬁcant association of
the metaconcentration scores with tests of executive
function (TMT B), consistent with another study in the
dialysis population.15 This is not surprising, and it
raises the possibility of the metaconcentration mea-
surement as an effective proxy/complement to objec-
tive tests of executive brain function. This remains toTable 6. Association of metacognition scales with objective tests of
cognition
Objective cognition test n Parameter estimate (95% CI) P value
Adjusted (for CCI, BDI, and education) regressions with metamemory as the outcome
TMT B (per 10-s increase) 144 0.09 (0.19, 0.02) 0.097
TMT A (per 10-s increase) 180 0.15 (0.39, 0.08) 0.19
3MS (per 10 score increase) 179 0.33 (0.66, 1.33) 0.51
Adjusted (for CCI, BDI, and education) regressions with metaconcentration as the
outcome
TMT B (per 10-s increase) 141 0.10 (0.17, 0.03) 0.004
TMT A (per 10-s increase) 177 0.10 (0.26, 0.06) 0.21
3MS (per 10 score increase) 176 0.43 (0.26, 1.12) 0.22
BDI, Beck Depression Inventory; CCI, Charlson Comorbidity Index; CI, conﬁdence in-
terval; s, second; TMT, Trail Making Test; 3MS, Modiﬁed Mini Mental State Examination.
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naire in the population with renal disease.
Other predictors of hospital-based modality choice
after adjustment of cognitive status include nonwhite
ethnicity and higher BDI and CCI scores. The latter
variables are known to be associated with and to
adversely affect both executive and global cognitive
functions.40–43
Cognitive impairment and/or depressive mood in
patients with ESRD can affect patient behaviors, atti-
tudes, and compliance.44,45 In a routine clinical
consultation of the predialysis patient in the UK,
patients spend considerable lengths of time being
assessed physically in preparation for commencement
of dialysis. Communication with the health care team is
less than ideally placed to identify all but the most
obviously cognitively impaired patients. In these
instances, depression may coexist or even overlap.
Although some units provide their patients with access
to psychotherapy, the vast numbers of practitioners
may be oblivious to the insidious development of a
psychopathological state in their patients. In 1 study
involving physicians’ estimation of dialysis patients’
cognitive ability during clinical consultations, it was
found that doctors had a tendency to underestimate the
deﬁciency when it was present, and only 4 of the 21
impaired patients were classiﬁed by their doctor as
being cognitively impaired.46 In the same study, doc-
tors could not identify 25.5% of patients who were
depressed, and 45% of those depressed were also found
to be cognitively impaired. This knowledge is impor-
tant not only for the decision-making phase but
thereafter for dialysis. Unidentiﬁed cognitive deﬁcits
may explain nonadherence with diet and ﬂuid man-
agement, and also disruptive behaviors on the dialysis
unit. Many CKD patients also report sleep disturbances,
and these can directly affect memory and concentra-
tion.47 In 1 study of CKD-4/5 patients, sleep-disordered
breathing was detected in 49.1% of patients.48 This
group also scored poorly on tests of working and
verbal memory, attention, and psychomotor speed.
There is also evidence from literature linking age,
cognition, and other individual characteristics with
health literacy in advanced age.49 The ﬁnding that
impaired health literacy in older age is in part a func-
tion of cognitive decline even among persons without
dementia necessitates interventions to reduce cognitive
demands, particularly complex reasoning abilities and
memory from patients, inherent in the health literature
materials and decision-making aids used by patients
with even milder degrees of cognitive impairment.
The question of cognition assessment is therefore
important today from a research perspective to answer
several questions regarding pathophysiology, potentialKidney International Reports (2016) 1, 240–249pharmacological and nonpharmacological interven-
tions, the timing of commencement of these inter-
ventions, the appropriate manner of monitoring, and
the ideal combination of tests, among other factors,
notwithstanding the implications of negative tests on
patient behavior and the health care team’s practice.
Our study has several limitations. The cross-
sectional study design does not conﬁrm the causal
impact of cognition on the reported choice of modality.
The limited data on TMT part B demonstrated the
difﬁculty of lack of “effort” on the patients’ and the
administrator’s part to “try hard” at the neuropsy-
chological tests, making the results of our study show a
relatively smaller proportion of predialysis patients as
having signiﬁcant cognitive impairment. Despite the
limitations, the study highlights some important prac-
tice points. There may be a role for subjective cognition
assessment as a measure of patients’ ability to under-
take self-care tasks. These patients may well need extra
support to cope with the burden of the disease.
In conclusion, patients’ own perception of their
cognitive ability has an important association with self-
care modality choice. This may offer a reliable assess-
ment tool in clinical practice to understand patient
phenotype. The subjective report of “metaconcentra-
tion” is signiﬁcantly associated with poorer outcome on
the Trail Making Test part B, a test of executive brain
function. Several areas of unmet need in understanding
cognition in kidney disease should provide the basis
for future research.
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